Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.
- 1 January 1985
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 31 (1) , 20-23
- https://doi.org/10.1093/clinchem/31.1.20
Abstract
Using gel filtration chromatography, we evaluated aluminum bound to albumin, transferrin, and other plasma proteins in the serum of patients on maintenance hemodialysis. The proportion of dialyzable aluminum, as determined by selective membrane ultrafiltration and flameless atomic absorption spectrometry, increased by more than fourfold on treatment with the metal chelator, deferoxamine. This ultrafiltration technique may prove useful for monitoring the proportion of aluminum mobilized during such therapy.This publication has 9 references indexed in Scilit:
- The Use of Deferoxamine in the Management of Aluminum Accumulation in Bone in Patients with Renal FailureNew England Journal of Medicine, 1984
- Plasma aluminum is bound to transferrinLife Sciences, 1983
- Improved determination of aluminum in serum and urine with use of a stabilized temperature platform furnace.Clinical Chemistry, 1982
- TREATMENT OF DIALYSIS OSTEOMALACIA WITH DESFERRIOXAMINEThe Lancet, 1982
- ALUMINUM DISTRIBUTION IN SERUM FOLLOWING HEMODIALYSIS1982
- Aluminum removal by hemodialysisKidney International, 1981
- SERUM BINDING OF ALUMINUM1979
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A FATAL ENCEPHALOPATHY IN CHRONIC HÆMODIALYSIS PATIENTSThe Lancet, 1976